Balchem Corporation today announced that Remco de Boer has joined the company as European Sales Manager for the Human Food, Pharma and Nutritional business unit.
Mr. de Boer has over ten years of sales experience promoting functional ingredients, including Choline, to supplement, infant formula, bakery, flavor, starch and sweetener industries in Europe and Asia. He has held key sales positions at Van Eeghen Group of Amsterdam and most recently at Meelunie BV of Amsterdam. His primary responsibility will be to manage the Balchem European Human Choline business, as well as introduce novel products and technologies.
“We anticipate significant growth in our European business to be driven by increasing consumer awareness and demand for choline plus a portfolio of new products targeting the supplement, wellness and bakery sectors. We expect Mr. de Boer’s efforts to compliment our distributor network and accelerate our performance,” said Eric Smith, Balchem’s Vice President of Marketing and Sales, Food, Pharma and Nutrition.
Mr. de Boer holds an HEAO Degree. His office will be based in Amsterdam and his contact information is as follows.
Balchem Trading B.V.
PO Box 14520
1001 LA Amsterdam
Tel +31 20 623 1520
Fax +31 20 421 4866
Mobile +31 6 5342 1545
Balchem Corporation consists of three business segments: ARC Specialty Products; Food, Pharma and Nutrition; and Animal Nutrition and Health. Through ARC Specialty Products, Balchem provides specialtypackaged chemicals for use in healthcare and other industries. The Food, Pharma and Nutrition segment provides proprietary microencapsulation, granulation and agglomeration solutions to a variety of applications in the human food, pharmaceutical and nutrition marketplaces. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets and certain derivative products into industrial applications.
Forward Looking Statements
This release contains forward-looking statements, which reflect Balchem’s expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem’s expectations, including risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31, 2008. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date.